Orbital decompression surgery among Medicare beneficiaries in the post‐teprotumumab era-Reference-Cited by-同舟云学术

Orbital decompression surgery among Medicare beneficiaries in the post‐teprotumumab era

Published:2024-05-08 Issue:9 Volume:14 Page:1505-1509
ISSN:2042-6976
Container-title:International Forum of Allergy & Rhinology
language:en
Short-container-title:Int Forum Allergy Rhinol

Author:

Bhat Akash M.¹²^ORCID,Soler Zachary M.¹,Schlosser Rodney J.¹³,Metson Ralph B.⁴,Rathi Vinay K.¹⁵^ORCID

Affiliation:

1. Division of Rhinology and Sinus Surgery Department of Otolaryngology–Head and Neck Surgery Medical University of South Carolina Charleston South Carolina USA

2. Department of Otolaryngology‐Head & Neck Surgery Drexel University College of Medicine Philadelphia Pennsylvania USA

3. Department of Surgery Ralph H. Johnson VA Medical Center Charleston South Carolina USA

4. Department of Otolaryngology–Head & Neck Surgery Massachusetts Eye and Ear Infirmary Boston Massachusetts USA

5. Department of Otolaryngology–Head & Neck Surgery The Ohio State University Columbus Ohio USA

Abstract

Key points

Utilization of orbital decompressions (ODS) increased (CAGR: +3.2%) from 2000 to 2019.

FDA approved teprotumumab in January 2020; ODS utilization decreased (CAGR: −14.9%) from 2019 to 2022.

In 2022, total spending was substantially higher for teprotumumab ($325 million) than surgery ($580,000).

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/alr.23358

Reference10 articles.

1. Endoscopic and external approaches for orbital decompression: an analysis of trends from a U.S. perspective

2. Orbital decompression for the management of thyroid eye disease: An analysis of outcomes and complications

3. US Food and Drug Administration.Tepezza. Accessed March 26 2024.https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761143s023lbl.pdf

4. Federal Trade Commission. In the matter of Amgen Inc. a corporation and Horizon Therapeutics Plc a corporation.2023. Accessed April 1 2024.https://www.ftc.gov/system/files/ftc_gov/pdf/Amgen‐Horizon‐Part‐III‐Complaint‐PUBLIC.pdf

5. Centers for Medicare & Medicaid Services.Medicare Part B spending by drug.2024. Accessed March 26 2024.https://data.cms.gov/summary‐statistics‐on‐use‐and‐payments/medicare‐medicaid‐spending‐by‐drug/medicare‐part‐b‐spending‐by‐drug